Cite
HARVARD Citation
Huang, X. et al. (n.d.). Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study. Cancer medicine. pp. 1043-1055. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Huang, X. et al. (n.d.). Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study. Cancer medicine. pp. 1043-1055. [Online].